ArticleACS omega2025
Study on the Construction and Anti-Tumor Effect of aPDL1/aMUC1 Double Antibody Modification of Doxorubicin Liposome.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the primary treatments for cancer have included chemotherapy, radiotherapy, and surgery. However, challenges such as poor prognosis, high recurrence rates, low survival rates, and diminished quality of life persist in cancer management. Recently, immunotherapy has emerged as a potent therapeutic approach for treating tumors. To this end, we developed antibodies for mucin 1 (MUC1) and programmed cell death ligand 1 (PD-L1) to functionalize liposomes and incorporate doxorubicin (DOX) (DOX-aMUC1/aPDL1-Lip). This formulation is designed to enhance its targeting capability and antitumor activity against cancer cells. The DOX-aMUC1/aPDL1-Lip formulation demonstrated significant antitumor effects both in vivo and in vitro, effectively inhibiting tumor cell growth. Utilizing antibodies against PD-L1 and MUC1 to modify liposomes represents a novel strategy for cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.